Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab + Ipilimumab + Nivolumab in Metastatic NSCLC
NCT05144529Phase 2Terminated
- Start
- Mar 2022
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of evolocumab in non-small cell lung cancer (NSCLC) (2 arms). Primary endpoints: Dose-limiting Toxicity at 30 days and Change in CD3+ Tumor Infiltrating Lymphocytes at day 29. Started Mar 2022; status: terminated.
02
Drugs
evolocumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05144529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05144529.